Working hours:

We accept orders 24/7

0
My order
Add items to wish list
Add items to comparison

Indosine 30

SKU 7030100
In stock
Description

PRODUCTS DESCRIPTION

One of the perspective directions in fight against oncological diseases is onco-prophylaxis. Due to steady growth of incidence rate, is needed development, creation and introduction in practice the new highly effective preparation, reducing risk of onco-process development. Application of vitamin- co-enzyme preparations, membrane-stabilizers, immunomodulators, antioxidants and enterosorbents has very positive influence. 'Indosine' has all the above-mentioned combinations and offers new perspectives of onco-process development prevention. 

 

 

Recommended:

  • increased risk of oncological diseases,
  • existence of pretumoral diseases,
  • in complex treatment of tumors,
  • recurrent tumors,
  • chemoradiotherapy,
  • antibiotic therapy,
  • rehabilitation after surgical interference,
  • allergies.

 

 

Ingredients:

microcrystalline cellulose (carrier); lactose (volume enhancer); potato starch (carrier); shellac (glazing agent); fatty acid calcium salts (anti-creasing agent); catalase; superoxide dismutase (from barley (Hordeum vulgare) germ extract); coenzyme Q10; indole-3-carbinol (from broccoli inflorescences); Broccoli (Brassica oleracea) inflorescence extract; maltodextrin (carrier).

Recommended as a source of coenzyme Q10 and indole-3-carbinol.

Recommendations for use:

adults by 1 tablet once a day, with meal. Do not bite through before taking tablet. Course duration is 4-6 weeks. It is allowed to repeat the course within a year, if needed.

€40
€56
Compare
Sign in
to add this item to wishlist
%
Sign in to see your personal discount
A new review or comment
Rate this item
Send
Up

We care about your privacy

This website uses cookies for marketing and statistical purposes and for a secure and optimal site experience. You can change this in your browser settings. Click on the «Accept cookies» button to consent using cookies. You can read more on the User agreement page.